MatTek Life Sciences

MatTek is exhibiting and presenting this week at the Association of Inhalation Toxicologists Annual Conference. Dr. Seyoum Ayehunie is presenting a poster on the development of multi-species airway tissue models. One of the challenges in the adoption of NAMs is the existence of large databases of animal toxicity data which are not directly translatable to data obtained from human in vitro airway tissue models due to species differences. To close that translational gap, Dr. Ayehunie and our R&D group have developed airway models from cells harvested from rats and non-human primates (NHP) to compare data to EpiAirway, MatTek's human airway model. These translational tools are vital to predicting airway inhalation toxicity and for bridging the in vitro-in vivo knowledge gap to reliably predict human responses, while providing an alternative approach to animal experimentation. Download the poster: https://bit.ly/3TxIbtV #betterscience #translationalbiology

MatTek scientists presented posters with new research at the EUROTOX Congress in Copenhagen, Denmark, last week. Posters include information on the development of our groundbreaking new EpiKidney tissue model, multi-species translational biology, and pre-validation of the EpiDerm model for skin sensitization. See what we've been working on and download copies of our posters: https://bit.ly/4emYDVK #betterscience #eurotox2024

🌍 Expanding Global Reach: MatTek Enters the Chinese Market through Strategic Partnership with CellEx I am thrilled to announce a groundbreaking partnership between MatTek Life Sciences and CellEx, a leading life sciences laboratory in China! This collaboration marks a significant milestone for MatTek as we license our cutting-edge in vitro human tissue technology to CellEx, enabling the production of our advanced tissue models within China. This strategic move not only expands our global footprint but also aligns with our mission to provide reliable, human-relevant testing solutions across the globe. By joining forces with CellEx, we are opening new doors for researchers and companies in China to access innovative tools for research, pharmaceutical development, and safety testing. Our partnership with CellEx represents a major step forward in meeting the growing demand for ethically produced, human-relevant tissue models in one of the world’s most dynamic markets, This collaboration is poised to drive innovation and foster the integration of Chinese tissue engineering technology with international standards, paving the way for significant advancements in the life sciences field. #LifeSciences #TissueEngineering #ResearchInnovation #MatTek #China #Biotechnology

NEWS: We're thrilled to announce that MatTek has licensed its groundbreaking in vitro human tissue technology to CellEx, a leading life science laboratory in China. In alignment with our mission to expand access and to reliable 3D models worldwide, CellEx will produce our portfolio of organotypic human tissues using our proprietary technology. This strategic partnership marks a major milestone in expanding the global reach of our advanced tissue models, and enabling researchers in China to access superior, human-relevant solutions for research, pharmaceutical development, and safety assessments. Read more: https://bit.ly/4e9XkcO #betterscience #innovation

Our colleagues, Alonso Alain and Viktor Karetsky, participated in a seminar organized by Kurabo Industries LTD, our valued partner and distributor in Japan. This seminar gathered numerous attendees from various industries such as cosmetics, medical devices, and pharma. Viktor presented and led a discussion on our ongoing projects including the pre-validation of toxicity assays using our EpiVaginal and EpiAirway models, as well as development of MatTek’s new tissue models such as EpiLiver and EpiKidney. After the seminar a lively Q&A session took place. In the following days the MatTek and Kurabo team exhibited at the 2024 Japan Society of Toxicology meeting held in Fukuoka and presented a poster. We are always grateful for the chance to educate and inform others around the globe about the capabilities of our technology, and the future of testing! #betterscience #collaboration #japan

Want to know more about how in vitro science is bridging the gap between animal testing and human results? This article goes into greater detail about our work with Charles River Laboratories to develop a New Approach Methodology (NAM) inhalation toxicology test to reduce reliance on traditional animal research methods. #betterscience #NAMs

MatTek had the pleasure of speaking and exhibiting at the Massachusetts State House in support of H.850 sponsored by Representative Jack Patrick Lewis and Senator Mark Montigny. The bill would require manufacturers to use effective, non-animal testing methods when available for cosmetics, household cleaners, and industrial chemicals. MatTek produces many types of lab-grown human tissues that accompany test protocols validated by global regulatory agencies, such as the OECD - OCDE, that are utilized by companies worldwide to ensure the safety and efficacy of their consumer products. The importance of legislative leadership to encourage the acceptance of NAMs cannot be overstated, and we are proud to support this effort in our home state with science-based solutions produced in Massachusetts labs. Many thanks to The Humane Society of the United States for organizing this event! #nonanimaltesting #betterscience #biotechsolutions

Earlier this month, MatTek's Chief Scientific Officer, Dr. Seyoum Ayehunie, presented a poster on groundbreaking work performed by our R&D team under his leadership. The development of a vascularized, metastatic colorectal cancer model for drug testing can have far reaching impacts from medical research to patient outcomes. This project is born of our partnership with NEXT Oncology and supports the goal of utilizing their inventory of patient-derived cancer cells to replicate cancerous tumors in vitro, so that more effective therapies can be developed by medical and pharmaceutical researchers. Download the poster: https://bit.ly/3RHfFVQ

ICYMI: MatTek, in collaboration with Charles River Laboratories has been awarded a grant from the Foundation for Chemistry Research & Initiatives to advance non-animal research. The program will develop a new approach method (NAM) for inhalation toxicology. As leaders in the field of human tissue engineering, and the creators of EpiAirway, MatTek is uniquely qualified to lend its expertise to the project. “This partnership marks a pivotal moment where innovation and collaboration will lead us toward safer and more reliable outcomes for all," said MatTek CEO Alex Armento. Read more: https://bit.ly/3z8QLrK #betterscience #NAMs

Don't miss this opportunity to learn about NEW patient-derived tumor models by MatTek, and their role in an automated workflow that combines human biology and technology for unprecedented preclinical insight. Register now: https://lnkd.in/grHujeWu